A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

NCT06410534 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped PI left NIH.

Conditions

Colorectal Cancer
Gastroesophageal Cancer

Interventions

DRUG: nivolumab
DRUG: ipilimumab

Sponsor

National Cancer Institute (NCI)